Disease Browser
Select a cancer type to view subtype-specific genomic testing recommendations by stage.
Solid Tumors
Non-Small Cell Lung Cancer
NSCLC accounts for ~85% of all lung cancers. It is the most genetically complex solid tumor with the largest number of actionable driver mutations. Comprehensive molecular profiling is recommended for all advanced/metastatic NSCLC and for select resectable cases where adjuvant targeted therapy may be indicated.
Breast Cancer
Breast cancer is the most common cancer in women worldwide (~30% of all female cancers). Molecular subtyping — driven by hormone receptor (ER/PR) and HER2 status — defines treatment strategy and genomic testing priorities. Comprehensive biomarker profiling is required for all invasive breast cancers, with additional tests indicated by stage and subtype.
Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer worldwide. Molecular profiling — particularly RAS/RAF mutational status, MSI-H/dMMR status, HER2 amplification, and NTRK fusions — directly guides first-line and subsequent therapy selection. Comprehensive biomarker testing is recommended at diagnosis for all stages with metastatic potential.